Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression

Acta Psychiatrica Scandinavica

Volumn 96, Issue 2, 1997, Pages 134-141

  Tanghe, A ^a   Geerts, S ^b   Van Dorpe, J ^c   Brichard, B ^d   Bruhwyler, J ^d   Geczy J ^d  

^a Biol Psychiatrie en co Therapie   (Belgium)

^b Dept of Psychiatry   (Belgium)

^c AZ Heilig Hart   (Belgium)

^d Therabel Pharma Belgium   (Belgium)

Author keywords

Antidepressant; Major depression; Moclobemide; Monoamine oxidase inhibitor; Pirlindole

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PIRLINDOLE;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TABLET; TACHYCARDIA; TREMOR; VOMITING; XEROSTOMIA;

EID: 0030873243     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1997.tb09918.x     Document Type: Article

References (30)

1. VERSIANI M, OGGERO U, ALTERWAIN P et al. A double-blind comparative trial of moclobemide vs. imipramine and placebo in major depressive episodes. Br J Psychiatry 1989: 155: 72-77.
2. DAVIS JM. Antidepressant drugs. In: KAPLAN HI, SADOCK BJ, ed. Comprehensive textbook of psychiatry. Vol. 4. Baltimore, MD: Williams and Wilkins, 1985: 1513-1537.
3. MCGRATH PJ, STEWART JW, HARRINSON W. Phenelzine treatment of melancholia. J Clin Psychiatry 1986: 47: 420-422.
4. LAUX G, CLASSEN W, SOFIC E et al. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder. J Neural Transm 1990: 32: 189-195.
5. AMREIN R, HETZEL W, STABL M, SCHMID-BURGK W. RIMA - a new concept in the treatment of depression with moclobemide. Int Clin Psychopharmacology 1993: 7: 123-132.
6. FITTON A, FAULDS D, GOA KL. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992: 43: 561-596.
7. DA PRADA M, CESURA AM, KETTLER R, ZÜRCHER G, HAEFELY W. Conversion of the neurotoxic precursor 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine into its pyridinium metabolite by human platelet monoamine oxidase type B. Neurosci Lett 1985: 57: 257-262.
8. KETTLER R, DA PRADA M, BURKARD WP. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand 1990: 82: 101-102.
9. CASSACHIA M, CAROLEI A, BARBA C et al. A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. Pharmacopsychiatry 1984: 17: 122-125.
10. GUELFI JD, PAYAN C, FERMANIAN J, PEDARRIOSSE AM, MANFRIEDI R. Moclobemide versus clomipramine in endogenous depression. A double-blind randomized clinical trial. Br J Psychiatry 1992: 160: 519-524.
11. BAKISH D, BRADWEJN J, NAIR N, McCLURE J, REMICK R, BULGER L. A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology 1992: 106: S98-S101.
12. BOUGEROL T, UCHIDA C, GACHOUD JP, KÖHLER M, MIKKELSEN H. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM-III). A French/Swiss double-blind trial. Psychopharmacology 1992: 106: S102-S108.
13. LONNQVIST J, SINTONEN H, SYVÄLAHTI E et al. Anti-depressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand 1994: 89: 363-369.
14. REYNAERT C, PARENT M, MIREL J, JANNE P, HAAZEN L. Moclobemide versus fluoxetine for a major depressive episode. Psychopharmacology 1995: 118: 183-187.
15. CHEN DT, RUCH R. Safety of moclobemide in clinical use. Clin Neuropharmacology 1993: 17: S50-S57.
16. MARTORANA PA, NITZ RE. The new antidepressant pirlin-dole: a comparison with imipramine and tranylcypromine. Arzneim Forsch Drug Res 1979: 29: 946-949.
17. MASHKOVSKY MD, ANDREJEVA NI. Pharmacological properties of 2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino [3,2,1-j,k] carbazol hydrochloride (pirlindole), a new anti-depressant. Arzneim Forsch Drug Res 1981: 31: 75-79.
18. MAJ J, MICHALUK J, RAWLOW A, ROGOZ Z, SKUZA G. Central action of the antidepressant drug pirlindole. Arzneim Forsch Drug Res 1986: 36: 1198-1201.
19. SCHRAVEN VE, REIBERT R. Hemmung der Monoaminoxidase A und B in Herz und Gehirn von Ratten durch Amitriptylin, Pargylin und Pirlindol (Inhibition of monoamine oxidase A and B of rat heart and brain by amitriptyline, pargyline and pirlindole). Arzneim Forsch Drug Res 1984: 34: 1258-1260.
20. DE WILDE JE, GEERTS S, VAN DORPE J, BRUHWYLER J, GECZY J. A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression. Acta Psychiatr Scand 1996: 94: 404-410.
21. PÖLDINGER W. Pirlindole: results of an open clinical study in out-patients and of a double-blind study against maprotiline. In: PICHOT P et al., ed. Psychiatry. The state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 283-289.
22. SALETU B, GRÜNBERGER J, RAJNA P, LINZMAYER L, SIMHANDL C. Examining pharmaco EEG-based predictions about the antidepressant action of pirlindol by double-blind clinical trials. In: PICHOT P et al., ed. Psychiatry. The state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 291-296.
23. SCHAPPERLE O, ECKMANN F, IMMICH H. A double-blind comparison of pirlindole with amitriptyline and imipramine. In: PICHOT P et al., ed. Psychiatry. The state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 297-302.
24. RENFORDT E. A comparison of pirlindole and amitriptyline in a double-blind controlled study. In: PICHOT P et al., ed. Psychiatry. The state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 311-317.
25. BLAHA L. A double-blind comparative study of pirlindole and amitriptyline in thirty depressive patients. In: PICHOT P et al., ed. Psychiatry. The state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, New York, 1983: 303-309.
26. LEHMANN E, KINZLER E, STUCKMANN A, HAHLHEGE M. A double-blind comparative study on the use of 225 mg pirlindole and 150 mg desipramine in the treatment of depressive in-patients. In: PICHOT P et al., ed. Psychiatry. The state of the art. Vol. 3. Pharmacopsychiatry. New York: Plenum Press, 1983: 321-327.
27. DE WILDE JE, MERTENS C, VAN DORPE J, BRUHWYLER J, GECZY J. Double-blind randomized controlled study of the efficacy and tolerability of pirlindole, a reversible inhibitor of monoamine oxidase A, and mianserin, in the treatment of depression. Hum Psychopharmacology, 1997: 12: 41-46.
28. VERSIANI M, NARDI AE, FIGUEIRA ILV, STABL M. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase A, compared with other antidepressants and placebo. Acta Psychiatr Scand 1990: 82: 24-28.
29. LINGJAERDE O, JORGENSEN J, STOREN R et al. A double-blind comparison of moclobemide and doxepin in depressed general practice patients. Acta Psychiatr Scand 1995: 92: 125-131.
30. NAIR NPV, AHMED SK, YING KIN NMK, WEST TEG. Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients. Acta Psychiatr Scand 1995: 91: 28-35.